Related Experiment Video

Updated: Aug 14, 2026

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Clinical development of mammalian target of rapamycin inhibitors

Janet E Dancey1

  • 1Cancer Treatment Evaluation Program, Division of Cancer Treatment and Diagnosis, Investigational Drug Branch/CTEP/DCTD/NCI, 6130 Executive Boulevard, EPN 7131, Rockville, MD 20854, USA. danceyj@ctep.nci.nih.gov

Hematology/Oncology Clinics of North America
|January 7, 2003
PubMed

Insights

Rapamycin and CCI-779 show strong anti-cancer effects in lab and animal studies. Early clinical trials indicate CCI-779 is safe and effective, prompting further cancer treatment research.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Rapamycin and CCI-779 demonstrate potent anti-proliferative effects against diverse human tumor cell lines.
  • These findings support the clinical investigation of rapamycin analogs in cancer therapy.

Purpose of the Study:

  • To evaluate the anti-proliferative activity and clinical potential of rapamycin and CCI-779 in cancer treatment.

Main Methods:

  • In vitro and in vivo studies assessing anti-proliferative activity.
  • Phase I clinical trials evaluating safety, tolerability, and anti-tumor activity of CCI-779.

Main Results:

  • Significant in vitro and in vivo anti-proliferative activity observed for rapamycin and CCI-779.
  • Preliminary Phase I data suggest CCI-779 is well-tolerated and exhibits anti-tumor effects.

Conclusions:

  • Rapamycin and CCI-779 represent a promising class of agents for cancer therapy.
  • Further research is needed to define the optimal role of these agents in clinical cancer treatment strategies.

More Related Videos

A Semi-Quantitative Drug Affinity Responsive Target Stability (DARTS) assay for studying Rapamycin/mTOR interaction05:28

A Semi-Quantitative Drug Affinity Responsive Target Stability (DARTS) assay for studying Rapamycin/mTOR interaction

Published on: August 27, 2019

Development and Application of Rapamycin-regulated Tyrosine Phosphatases06:56

Development and Application of Rapamycin-regulated Tyrosine Phosphatases

Published on: September 6, 2024

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...